期刊文献+

妊娠合并心脏病相关肺动脉高压诊疗进展 被引量:4

Advances on diagnosis and treatment in pregnancy combined with cardiac disease and pulmonary hypertension
原文传递
导出
摘要 肺动脉高压的突出特征是肺血管收缩和重塑,妊娠和性激素变化加重了心脏病相关肺动脉高压病情,死亡风险高。其临床诊疗过程较为复杂,需要结合患者临床表现、心功能、体格检查、肺动脉压力及生化检查等进行综合诊断。心脏病相关肺动脉高压患者妊娠风险高,目前已经取得了一系列诊疗进展,支持治疗包括氧疗和休息、容量管理和纠正贫血等,靶向药物通过扩张肺血管、降低肺血管阻力改善该类患者的预后,心衰和严重肺动脉高压者必要时进行非药物治疗,产后应延续靶向治疗和随访评估。 Pulmonary hypertension is characterized by pulmonary vasoconstriction and remodeling,aggravated by pregnancy and sex hormone changes,and a high risk of death associated with cardiac disease.The clinical diagnosis and treatment process is complicated and requires a comprehensive diagnosis based on clinical manifestations,cardiac function,physical examination,pulmonary artery pressure,and biochemical examination.Pregnancy increased the risk of heart disease combined with pulmonary hypertension,and currently there are a series of progress in the diagnoses and treatment,such as support treatment including oxygen therapy and rest,capacity management,correction of anemia,and targeted drugs through dilating pulmonary vassels and inhibiting the pulmonary vascular resistance,to improve the prognosis of these patients.Non-drug therapy may be adopted for the patients with heart failure and severe pulmonary hypertension when necessary.Targeted therapy and follow-up evaluation should be continued to postpartum period.
作者 张静 朱睿瑶 王卓 王慧娟 雷佳羲 詹丽英 ZHANG Jing;ZHU Ruiyao;WANG Zhuo;WANG Huijuan;LEI Jiaxi;ZHAN Liying(Dept.of Anesthesiology,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China;Dept.of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China)
出处 《武汉大学学报(医学版)》 CAS 2022年第4期590-595,共6页 Medical Journal of Wuhan University
基金 湖北省中央引导地方科技发展资金资助项目(编号:2020ZYYD004)。
关键词 肺动脉高压 妊娠合并心脏病 诊断 Pulmonary Hypertension Pregnancy with Cardiac Disease Diagnosis
  • 相关文献

参考文献4

二级参考文献59

  • 1荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:117
  • 2Rubin LJ. Primary pulmonary hypertention[J]. N Engl J Med, 1997, 336(2) : 111-117.
  • 3D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension, Results from a national prospective study[J]. Ann Intern Med, 1991, 115 (5) : 343-349.
  • 4Jing ZC, Parikh K, PulidoT, et al. Efficacy and safety of oral treprostinilmonotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial [J]. Circulation, 2013, 127 (5) : 624-633.
  • 5McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial [J]. J AmCoil Cardiol, 2010, 55 (18) : 1915-1922.
  • 6Vane J, Corin RE. Prostacyclin: a vascular mediator[J]. Eur J Vase Endovasc Surg, 2003, 26 (6) : 571-578.
  • 7Barst RJ, Rubin L J, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostaeyclin) with conventional therapy for primary pulmonary hypertension [J]. N Engl J Med, 1996, 334(5): 296-301.
  • 8McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy[J]. Circulation, 2002, 106 (12) : 1477-1482.
  • 9Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial[J]. Ann Intern Med, 2000, 132 (6) : 425-434.
  • 10Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyelin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study[J]. Eur Respir J ,1999, 13 (6) : 1351-1356.

共引文献479

同被引文献62

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部